In the last trading session, 61.11 million NLS Pharmaceutics Ltd (NASDAQ:NLSP) shares changed hands as the company’s beta touched -0.40. With the company’s per share price at $2.49 changed hands at $0.51 or 25.76% during last session, the market valuation stood at $6.16M. NLSP’s last price was a discount, traded about -735.34% off its 52-week high of $20.80. The share price had its 52-week low at $1.71, which suggests the last value was 31.33% up since then. When we look at NLS Pharmaceutics Ltd’s average trading volume, we note the 10-day average is 6.88 million shares, with the 3-month average coming to 1.18 million.
Analysts gave the NLS Pharmaceutics Ltd (NLSP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NLSP as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. NLS Pharmaceutics Ltd’s EPS for the current quarter is expected to be 0.
NLS Pharmaceutics Ltd (NASDAQ:NLSP) trade information
Instantly NLSP was in green as seen at the end of in last trading. With action 39.89%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 18.01%, with the 5-day performance at 39.89% in the green. However, in the 30-day time frame, NLS Pharmaceutics Ltd (NASDAQ:NLSP) is -8.46% down. Looking at the short shares, we see there were 85784.0 shares sold at short interest cover period of 0.04 days.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 7.15%.
NLSP Dividends
NLS Pharmaceutics Ltd is expected to release its next quarterly earnings report in March.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 6.0535% or 2.31 million shares worth $0.5 million as of 2024-06-30.
With 358.0 shares estimated at $891.0 under it, the former controlled 0.01% of total outstanding shares.
